Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a pioneering force in the biopharmaceutical industry, is headquartered in China (CN) and operates extensively across major global markets. Founded in 2017, the company has rapidly established itself as a leader in cell therapy, focusing on innovative treatments for cancer and autoimmune diseases. Gracell's core offerings include its proprietary FasTCAR™ technology, which enhances the efficacy and safety of CAR-T cell therapies, setting it apart in a competitive landscape. The company has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing healthcare solutions. With a strong market position and a dedication to transformative therapies, Gracell Biotechnologies continues to make strides in the biopharmaceutical sector, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Gracell Biotechnologies Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gracell Biotechnologies Inc.'s score of 96 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gracell Biotechnologies Inc., headquartered in China (CN), currently does not report any specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of AstraZeneca PLC, and therefore, it inherits climate commitments and targets from its parent organisation. As part of its corporate family relationship with AstraZeneca, Gracell Biotechnologies aligns with the sustainability initiatives and reduction targets set by AstraZeneca. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from AstraZeneca at a cascade level of 4. However, specific reduction targets or achievements for Gracell Biotechnologies have not been disclosed. While Gracell Biotechnologies has not established its own emissions data or reduction targets, it is positioned within an industry context that increasingly prioritises climate action and sustainability. The company is expected to adhere to the broader commitments of its parent company, AstraZeneca, which is actively working towards reducing its carbon footprint and enhancing its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gracell Biotechnologies Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
